Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $91.35, for a total value of $1,096,200.00. Following the completion of the sale, the insider now owns 1,040,313 shares of […]
Teacher Retirement System of Texas reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,002 shares of the company’s stock after selling 860 shares during the period. […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) CFO Timothy Eugene Sullivan sold 69,779 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $88.80, for a total transaction of $6,196,375.20. Following the sale, the chief financial officer now owns 77,713 shares in […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]